Podcasts about Reuss

Gesprek met zanger, dirigent en componist Jeroen Spitteler baar aanleiding van een toevallige ontmoeting bij het jubileum van uitgeverij Sjibbolet alwaar Jeroen een aantal liederen van Hildegard van Bingen te gehore bracht. Meer info over Jeroen: https://jeroenspitteler.nl/promenade/ Van zijn site: Als jongenssopraan en solist zong ik onder leiding van Maurice Pirenne in de Schola Cantorum van de Sint Jansbasiliek in Den Bosch. Na mijn studie Klassieke Talen aan de UVA, studeerde ik koordirectie bij Daniël Reuss aan het Conservatorium van Amsterdam. Daarnaast had ik les van onder meer Paul van Nevel, Jan Boogaarts en Jos van Veldhoven. Solozang studeerde ik bij Sasja Hunnego, aan het Koninklijk Conservatorium van Den Haag. Na jarenlang te hebben gezongen bij onder andere Cappella Amsterdam, de Nederlandse Bachvereniging en Cappella Pratensis, zing ik momenteel als bas bij Studium Chorale. Het repertoire waarmee ik mij als dirigent bezighoud loopt van de vroege middeleeuwen tot aan muziek waarvan de inkt maar net droog is, en van a capella koormuziek tot werken voor koor en orkest in grote bezetting. Mijn speciale liefde voor de polyfonie van de 16de eeuw heeft geleid tot de oprichting van Ensemble Hermes. Naast artistiek leider van Ensemble Hermes, ben ik vaste dirigent van Photonen vocaal ensemble in Amsterdam en van vrouwen-ensemble Les Dames Vocales. Daarnaast leid ik het Midsummer Ensemble, een intensief zomerproject voor koor en okest, en het Nederlands Projectkoor dat meerdere keren grote werken uitvoerde met Het Orkest en in 2019 de mis voor dubbelkoor van Frank Martin uitvoerde in de grote zaal van het Orkestgebouw te Amsterdam. Sinds enige jaren ben ik actief als componist. Op mijn naam staan meerdere werken voor vocaal ensemble en werken voor koor en (kamer)orkest, zoals de Sint Maartenscantate, Cinque pensieri di Gandhi en het onlangs voor Stg. Utrechts requiem geschreven ‘Jonge vrouw in afwachting van een hulphond'.

Kommet for at tjene

Was braucht es bei der Rehabilitation von Brandopfern? Wie bereitet sich die Aargauer Klinik auf weitere Patientinnen und Patienten vor? Wir haben mit den Verantwortlichen gesprochen. Weiter in der Sendung: · Die Aargauer Staatsanwaltschaft sucht Zeugen in Zusammenhang mit dem Tötungsdelikt in Neuenhof. Ein orangefarbener Lamborghini soll Ende Januar im Raum Neuenhof unterwegs gewesen sein. Menschen die ihn gesehen oder sogar fotografiert haben, sollen sich bei der Polizei melden. · Am 12.02.26 am Nachmittag findet über der Reuss zwischen Mellingen und Bremgarten eine Such- und Rettungsübung mit einem Helikopter statt.

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Etwa die Hälfte der Zürcher Gemeinden empfiehlt im Brief an die Steuerpflichtigen eine Software, um die Steuererklärung offline auszufüllen. Nur gibt es ausgerechnet diese Möglichkeit seit diesem Jahr nicht mehr. Weiter in der Sendung: · VS: Das Kantonsgericht sagt, dass der Brandfall in Visp 2024 nochmals aufgerollt werden muss. Es stellt sich die Frage, ob die Behörden ihre Pflichten wahrgenommen haben. · AG: Die Regierung will keine «Bade-Ampeln» an der Reuss. Das schreibt sie ihrer Antwort auf einen Vorstoss.

In this episode of GuildSomm: Into the Glass, newly minted Master Sommelier David Reuss joins host MS Chris Tanghe to blind taste three red wines. Before David starts tasting, they discuss the experience of passing the exam, the preparation and best practices that helped David reach that milestone, and what he plans to do next. David is the national education director for Jackson Family Wines. He previously worked in some of Colorado's best restaurants, including Frasca Food and Wine in Boulder and Shanahan's Steakhouse in Denver. David passed the Master Sommelier Exam in fall of 2025. Listen in and guess the wines along with David! Thanks for listening. If you enjoy this episode, please consider leaving us a review, as it helps us connect and grow the GuildSomm community. Cheers!

In this episode, 2026 AAEP President Sarah Reuss, VMD, DACVIM, joined us to discuss her goals for her term and what she believes are the biggest challenges facing the profession.The Business of Practice podcast is brought to you by CareCredit.This information is shared solely for your convenience. You are urged to consult with your individual advisors with respect to any information presented.Business of Practice Podcast Hosts, Guests, and Links Episode 131:Hosts: Dr. Amy Grice and Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (csisson@equinenetwork.com) | Connect with Carly on LinkedInGuest: AAEP President Dr. Sarah ReussPodcast Website: The Business of Practice

In this episode, 2026 AAEP President Sarah Reuss, VMD, DACVIM, joined us to discuss her goals for her term and what she believes are the biggest challenges facing the profession.The Business of Practice podcast is brought to you by CareCredit.This information is shared solely for your convenience. You are urged to consult with your individual advisors with respect to any information presented.Business of Practice Podcast Hosts, Guests, and Links Episode 131:Hosts: Dr. Amy Grice and Carly Sisson (Digital Content Manager) of EquiManagement | Email Carly (csisson@equinenetwork.com) | Connect with Carly on LinkedInGuest: AAEP President Dr. Sarah ReussPodcast Website: The Business of Practice

Guds planer

Der Jahreswechsel bringt neue Energie, frische Motivation – und eine Menge guter Vorsätze. Doch warum scheitern so viele genau daran?In dieser Folge spreche ich darüber, warum Ziele oft nicht erreicht werden – gerade von hochsensiblen oder vielbegabten Scannerpersönlichkeiten. Ich zeige dir, worauf es bei Zielsetzung wirklich ankommt, was dein inneres „Warum“ damit zu tun hat und warum emotionale Verbindung wichtiger ist als bloße Logik.

Hochsensible Scannerpersönlichkeiten wollen vieles: tief fühlen, schnell denken, alles richtig machen – und am besten noch niemanden enttäuschen. Doch dabei geraten sie oft in eine Endlosschleife der Selbstüberforderung.

Hochsensible Scannerpersönlichkeiten fühlen sich oft „anders“ – zu sensibel, zu schnell, zu tief. Und genau dieses Anderssein versuchen viele zu verstecken, kleinzuhalten oder sich in Systeme zu pressen, in die sie nie passen werden.In dieser Folge spreche ich darüber, warum genau dieses Anderssein kein Makel ist, sondern dein größter Erfolgsschlüssel – beruflich wie persönlich.Ich zeige dir:was Hochsensibilität und Scannerpersönlichkeit wirklich ausmachtwarum klassische Jobs dich oft überfordern oder unterfordernwie du deine Intuition endlich als inneren Kompass nutztwie du erkennst, ob du gerade deine Superkraft oder dein Verstand lenkstwarum du aufhören darfst, dich zu verbiegen – und anfangen darfst, du selbst zu seinDu bist nicht falsch, weil du viel wahrnimmst, tief fühlst und ständig neue Ideen hast.Du bist genial – und genau darin liegt dein Potenzial. ✨

Für hochsensible Scanner-Persönlichkeiten kann das Leben schnell zu laut, zu viel und zu chaotisch werden. Kein Wunder – denn sie nehmen mehr wahr, denken tiefer und fühlen intensiver als andere.Genau hier wird Spiritualität zum Rettungsanker. Nicht als Esoterik – sondern als innere Orientierung, Verbindung und Sinn. In dieser Folge spreche ich darüber, warum Spiritualität für Hochsensible und Scanner kein netter Zusatz, sondern oft eine innere Notwendigkeit ist.

Predigt von Heinz Reuss vom Sonntag den 07.12.2025

Predigt vom Samstag, den 22.11.2025, von Heinz Reuss

Die Reuss-Initiative hat genügend Unterschriften gesammelt. Sie fordert Grundrechte und Rechtspersönlichkeit für alle Gewässer im Kanton Luzern, um deren Schutz zu stärken. Weiter in der Sendung: · Politischer oder religiöser Extremismus bereitet der Luzerner Regierung Sorgen · Ewigkeitschemikalien in Lebensmittel - oberste Kantonschemikerin reagiert auf PFAS-Fund in Fischen des Zugersees

Seit Jahren klagen Anwohnende über den Lärm vom Waffenplatz Thun. Die Armee hätte bis Juli 2025 lärmsanieren müssen – doch passiert ist wenig. Nun schlägt sie eine Indoor-Schiesshalle oder Schallschutzfenster vor. Für die Betroffenen ist das Symptombekämpfung – sie fordern echte Ruhe. Weitere Themen (00:03:58 ) AG Fischtracking in Schweizer Flüssen liefert erste Erkenntnisse Die Unterwasserwelt ist noch immer ein weisser Fleck – auch in der Schweiz. Das will das ETH-Wasserforschungsinstitut EAWAG ändern: 600 Fische in Aare, Rhein, Reuss und Thur wurden mit Trackern versehen. Unterwassermikrofone zeichnen ihre Wege auf, zusätzlich wird ihre Körpertemperatur gemessen. Die Forschenden wollen verstehen, warum Fische wohin schwimmen – und wie sie auf steigende Wassertemperaturen reagieren. Nach einem Jahr gibt es nun erste Ergebnisse. (00:06:57) TG/GR Tüftler mit dem E-Ski heimlich auf Skitouren Was beim Biken längst Alltag ist, soll nun auch im Schnee gelten: Tourenskis mit eingebautem Motor. Ein Tüftler aus dem Thurgau testet seine E-Skies heimlich bei Nacht – aus Angst, jemand könnte ihm die Patent-Idee klauen. Auch ein Erfinder aus Südbünden werkelte am elektrischen Ski: Seine Version startet jetzt in die erste Testphase. (00:09:58) NW Kino Buochs feiert Comeback mit Ski-Film Nach 13 Jahren flimmert wieder ein Film über die Leinwand im Kino Buochs – dank dem leidenschaftlichen Kinofan Kobi Barmettler. (00:00) Er bringt den Streifen «Downhill Skiers» in seine Heimat, direkt nach der Première am «Zurich Film Festival». Im Fokus: die besten Skirennfahrer der Welt, darunter auch der Nidwaldner Marco Odermatt. Ob er persönlich vorbeischaut bei einer der elf Aufführungen? «Er hat zumindest nicht Nein gesagt», meint Barmettler. (00:13:01 ) ZH Wer ist eigentlich Nora Binkert? Sie kommt aus Eglisau und bringt die Schweiz zum Lachen: Nora Binkert, ein frisches Comedy-Talent mit trockenem Humor und scharfem Blick fürs Alltägliche. Auf Social Media erreicht sie mit ihren Videos zehntausende – vor allem junge Fans. Jetzt schafft sie den Sprung vom Handybildschirm ins Schweizer Fernsehen. Viele fragen sich: Wer ist diese junge Frau hinter den Videos?

Die Gemeinden Boniswil, Egliswil, Hallwil, Meisterschwanden, Seengen, Seon und Teufenthal wollen ihre Trinkwasserversorgung künftig gemeinsam organisieren. Hintergrund ist, dass es bei der Wasserversorgung im Seetal bereits heute teilweise zu Engpässen kommt. Weitere Themen in der Sendung: · In der Solothurner Gemeinde Zuchwil hat der Gemeinderat ein Mitglied per Amtszwang zum Vizepräsidenten ernannt. Das sorgt für Misstöne. · Mit Unterwassermikrofonen erforschen Wissenschaftlerinnen und Wissenschaftler in Bremgarten, wie sich Fische in der Reuss und anderen Schweizer Flüssen bewegen.

Der Gemeinderat von Zuchwil hat eines seiner Mitglieder per Amtszwang zum Vizepräsidenten gemacht. Der Amtszwang wird nur selten angewandt, und wenn, dann in kleinen Gemeinden, die ihre Ämter nicht besetzen können. Für eine grosse Gemeinde wie Zuchwil ist es die sehr grosse Ausnahme. Mehr zum Thema: · Wettingen: Lilian Studer, EVP, ist definitiv Gemeinderätin. Eine Nachzählung der Wahl von Ende September hat ergeben, dass das Wahlresultat korrekt ist. Anstatt acht Stimmen hat Studer nun sogar 12 Stimmen Vorsprung auf den Konkurrenten der Mitte-Partei. · Wohlen: Der Einwohnerrat lehnt den vom Gemeinderat geforderten höheren Steuerfuss für 2026 ab. Damit leben muss nun der neu gewählte Gemeindeammann Roland Vogt von der SVP, also von jener Partei, die immer gegen höhere Steuern kämpfte. Vogt schliesst nicht aus, dass auch er die Steuern dereinst erhöhen muss. · Bremgarten: Ein Forschungsprojekt in der Reuss und anderen Flüssen untersucht, wie und warum Fische wandern. Verwendet werden Hydrophone – Unterwassermikrofone, die Fische telemetrisch vermessen können. Dazu werden Fische mit Sendern versehen.

Wenn der Beruf Berufung ist: Karin Riegger und Christoph Schoop im Gespräch mit Michèle Schönbächler Christoph Schoop – Zwischen Handwerk und Zukunftsdenken Christoph Schoop ist in einem Umfeld aufgewachsen, das von unternehmerischem Pioniergeist geprägt war. Sein Vater gründete in Dättwil 1955 eine Spenglerei, welche die Spenglertechnik revolutionierte, und damit früh Zeichen in der Branche setze. Christoph Schoop trat nach seiner Ausbildung zum Spengler in den Betrieb ein und übernahm bereits in jungen Jahren die Leitung. Heute denkt er über das klassische Handwerk hinaus: Er investiert in Grundstücke und entwickelt Projekte, die auf Nachhaltigkeit und Machbarkeit ausgerichtet sind. Mit dem „Wikkelhouse“ verfolgt er ein innovatives Wohnkonzept, welches das Leben auf kleinem Raum neu interpretiert. Seine unternehmerische Haltung ist klar: wirtschaftlich denken, aber mit Augenmass – gewinnorientiert, aber nicht gewinnmaximiert um jeden Preis. Schon als Kind genoss er die Natur im Ferienhaus an der Reuss – und noch heute spielt die Natur für ihn eine wichtige Rolle – als Ort der Erholung und als Quelle für neue Ideen. ________________________________________ Karin Riegger - Neue Wege nach einem unerwarteten Umbruch Während 12 Jahren war Karin Riegger im Verkauf der Familienunternehmung Weinkeller Riegger AG tätig, betreute ihre Gastronomie-Kunden in der ganzen Schweiz und bereiste die unterschiedlichsten Weingüter. Es schien logisch, dass sie die Nachfolge ihres Onkels als Geschäftsführerin antreten würde. Die innerfamiliäre Übergabe der Unternehmung kam jedoch nicht zustande – stattdessen wurde das Familienunternehmen an einen Grosskonzern verkauft. Diese Wendung führte zu einem beruflichen Neustart. Der Bewerbungsprozess mit Mitte 40 war für die Aargauerin anspruchsvoll, aber auch eine Gelegenheit zur persönlichen Weiterentwicklung. Heute ist Karin Riegger Bereichsleiterin Bildung bei Holzbau Schweiz und bringt ihre Erfahrungen und ihr Engagement in die Branche ein. Sie lebt mit ihrem Partner und ihren drei Kindern in Mellingen/AG. In den Ferien tauscht sie regelmässig das Wohnhaus mit anderen Familien – eine Form des Reisens, die ihr neue Perspektiven und Freundschaften eröffnet hat. Besonders prägend war ein halbes Jahr in Australien, wo sie gemeinsam mit ihrer Familie lebte und täglich zur Schule ging. _________________________________________ Moderation: Michèle Schönbächler Karin Riegger und Christoph Schoop sind zu Gast im Persönlich am Sonntag, 28. September 2025 im Kurtheater Baden/AG. Türöffnung ist um 9 Uhr. Das Publikum ist gebeten, bis 9.30 Uhr einzutreffen. ___________________________________________ Das ist «Persönlich»: Jede Woche reden Menschen über ihr Leben, sprechen über ihre Wünsche, Interesse, Ansichten und Meinungen. «Persönlich» ist kein heisser Stuhl und auch keine Informationssendung, sondern ein Gespräch zur Person und über ihr Leben. Die Gäste werden eingeladen, da sie aufgrund ihrer Lebenserfahrungen etwas zu sagen haben, das über den Tag hinaus Gültigkeit hat.

Dr. Joshua Reuss joints that podcast to discuss the latest changes to the living guideline on stage IV NSCLC with driver alterations. He discusses the new evidence for NSCLC with EGFR mutations and NRG1 fusions and how this impacts the latest recommendations from the panel. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1” at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-01061 Brittany Harvey: Hello and welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1." It's great to have you here today, Dr. Reuss. Dr. Joshua Reuss: Thank you. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So to dive into what we're here today to talk about, Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non–small cell lung cancer with driver alterations is updated on an ongoing basis. So what prompted this latest update to the recommendations? Dr. Joshua Reuss: Yes, thank you. It's very important that we have living guidelines that are continuously updated. We obviously don't live in a static environment where things are non-changing, and we really need to apply the most up-to-date and current evidence to treat our patients with the most effective strategies, the most groundbreaking strategies. And so to have guidelines that can be disseminated, particularly these ASCO guidelines, to treating providers is incredibly important. So, with any of these updates, we review ongoing studies, published work, for the quality of evidence to see if it's something that warrants making adjustments to our guidelines or at least incorporating the information so that providers can review it and incorporate this into their own personal decision-making. So in this particular update, we reviewed evidence particularly pertaining to EGFR-mutated non–small cell lung cancer and non–small cell lung cancer harboring an NRG1 fusion. Brittany Harvey: Yes, certainly there's a lot of new evidence in the advanced non–small cell lung cancer field, and so we appreciate the panel's continuous review of this evidence. So then you just mentioned two separate areas where the panel reviewed new evidence. So starting with that first one, what updated evidence did the panel review on first-line treatment options for patients with EGFR alterations, and how did this impact the recommendations? Dr. Joshua Reuss: Yes, so advanced EGFR-mutated non–small cell lung cancer, at least with classical activating alterations - that is our exon 19 deletions and our exon 21 L858R mutations - is something that's really evolved rapidly in the last few years. You know, for many years, we basically, for the frontline treatment setting, were saying, "Okay, we have a targeted therapy, osimertinib. We're going to give that, and we're going to see what effect we can get out of that," with, you know, a median time of duration of treatment response averaging around 18 months, knowing that there are some that that's a lot longer and some that are a lot shorter. But recently, we've seen a lot of data emerging on combination strategies. The guideline has already been updated to incorporate two of these combinations: osimertinib with chemotherapy based off of the FLAURA2 trial, and then the combination of amivantamab with lazertinib based off of the MARIPOSA trial. And that was data on progression-free survival that was published and led to those particular recommendations. Now, more recently, we've seen data come out in smaller, randomized studies for other combinations. And more recently, we reviewed the RAMOSE study. So this was a phase II, open-label, randomized trial for patients with tyrosine kinase inhibitor–naive and really, treatment-naive advanced EGFR-mutated non–small cell lung cancer harboring one of these two classical EGFR alterations, randomized to either osimertinib alone or osimertinib with the combination of ramucirumab, which is an anti-VEGF agent. There's been a lot of data, preclinical and clinical, for the role of VEGF blockade, particularly in EGFR-mutated non–small cell lung cancer, so exploring the combination of this for synergy in the frontline setting really made a lot of sense. So again, this was a phase II trial that randomized patients prospectively to one of these two regimens. The population here is really what we typically see with EGFR-mutated non–small cell lung cancer, predominantly a younger population - median age on this study was 65 - predominantly female - 71% female - and predominantly nonsmokers. Now, what this study showed was that at a median follow-up of 16.6 months, the progression-free survival favored the combination arm with a median progression-free survival of 24.8 months with the combination of osimertinib plus ramucirumab versus 15.6 months for osimertinib alone, for a hazard ratio of benefit of 0.55. The landmark one- and two-year endpoints for progression-free survival also favored the combination arm, and response rates were relatively comparable between groups, with overall adverse events being more frequent in the combination group, specifically high blood pressure, proteinuria, and epistaxis, which are our common adverse events related to VEGF-blocking agents. So, it's good to see data in this space. Now, of note, though, this was a phase II study, so not a phase III level of evidence. In addition, when looking at the population, this was a randomized, multicenter study, but it was a US-only population. There was also some imbalance in the number of visits between arms, so the combination arm was seen more frequently than the arm that got osimertinib alone. Now, the imaging assessments were no different, but obviously this could lead to potential confounding, at least in timing of awareness of potential side effects and and things being brought to the attention of investigators. So very promising data here, but because, you know, of this being a phase II study, this actually led to no changes in the guideline at this time. Brittany Harvey: Understood. Yes, as you mentioned prior, it's important to understand the full body of evidence and to review the trials even when it doesn't impact the recommendations. Dr. Joshua Reuss: And I will say that, you know, there is an ongoing phase III study looking at a very similar combination. It's the phase III ECOG-ACRIN trial of the combination of osimertinib plus bevacizumab versus osimertinib alone in this specific population. So, you know, I think we will see phase III–level data for a combination of VEGF with osimertinib, but again, promising phase II data that did not lead to a change in the recommendation at this time. Brittany Harvey: Absolutely. We'll look forward to that ongoing trial to learn more about combination in this patient population. So then moving to that second patient population that you mentioned earlier where the panel reviewed evidence, what is the updated evidence and recommendation for patients with NRG1 fusions? Dr. Joshua Reuss: Yeah, so this was an exciting update that we made more recently with this unique iteration of the living guidelines. So, NRG1 fusions, this is perhaps a newer kid on the block in terms of driver alterations that has been known to be identified in non–small cell lung cancer among other solid tumors. It is very rare, occurring in less than 1% of solid tumors, but something that we know is a unique oncogenic pathway that can lead to oncogenesis and cancer development, including in non–small cell lung cancer. So up until now, unfortunately, there have not been targeted therapies that target this unique alteration. It's somewhat different than other driver alterations where there's a top-level signaling change in a protein. This is more of a ligand alteration that then alters, that then enables activation of more classical pathways, but again, through upregulation of a unique ligand. So a slightly different pathway but something that we know should be able to be targeted to promote patient survival for those with NRG1 fusions. So the therapy here is a therapy called zenocutuzumab. It's an IgG1 bispecific antibody against HER2 and HER3. So it prevents the downstream dimerization and signaling that occurs as a result of this NRG1 fusion and upregulation of the NRG1 signal. This was, as you can imagine with a rare alteration, a large phase II registrational study that examined this in advanced solid tumors containing the NRG1 fusion. This is the NRG1 registrational trial. And this study enrolled patients with advanced solid tumors who had progressed on prior therapy. Patients were treated with zenocutuzumab 750 milligrams IV every two weeks. Among 158 response-evaluable solid tumor patients, the response rate was 30%, median duration of response of 11.1 months, and a median progression-free survival of 6.8 months. Now, in those with non–small cell lung cancer, that made up 93 response-evaluable patients, very similar outcomes there: a response rate of 29%, median duration of response of 12.7 months, and a median progression-free survival of 6.8 months. This therapy did appear to be well tolerated. The most common higher-grade emergent side effects - grade 3 or higher - were anemia occurring in 5% and elevated liver numbers occurring in 3%. So this is a subsequent-line study, so this led to the updated recommendation that clinicians may offer zenocutuzumab in the subsequent-line setting for patients with advanced non–small cell lung cancer who harbor NRG1 fusions. So I think this does speak toward the incredible importance of next-generation sequencing and molecular testing for patients, particularly to include testing that looks at the RNA. These large fusions can sometimes be very challenging to detect on DNA sequencing platforms alone, so it's important to, if you have a high level of suspicion for an alteration like this, perhaps some of the mucinous adenocarcinomas where it's been challenging to find a driver alteration, and it's someone who is a never-smoker, really would want to include molecular testing that assesses the RNA level and not just the DNA. Brittany Harvey: Absolutely. It's important to have all the biomarkers available so that clinicians are able to use that to inform their decision-making. So then, given these changes in the guideline, what should clinicians know as they implement this latest living guideline update? And how do these changes impact patients? Dr. Joshua Reuss: Yeah, I think talking in reverse order of what we just discussed here, there is a new guideline update for NRG1 fusions. So I think making sure that that's being evaluated, that clinicians are testing for that and really looking for that result that should be incorporated in in most next-generation large sequencing assays to get that result, but it's very important that that is not overlooked now that we do have a therapy that's available in the subsequent-line setting, though it is important to note that patients with NRG1 fusions, at least the limited data that there is suggests that the efficacy to standard chemoimmunotherapy regimens is overall poor. So physicians unfortunately might be facing this question for second-line therapy in patients with NRG1 fusions sooner rather than later. For the former, for EGFR-altered non–small cell lung cancer and how do we incorporate VEGF-containing regimens into these patients? Our guideline top-level update did not change based off of review of this new study, but it's important for clinicians to know what other combinations may exist. You know, there are phase III studies looking at this combination in the frontline setting. And of course, there is data on other bispecific molecules that incorporate VEGF in the subsequent-line setting, particularly a combination that includes the VEGF/PD-1 bispecific antibody ivonescimab that's being studied in the HARMONi-A trial for patients with EGFR-mutated advanced non–small cell lung cancer, for which we hope to get some more definitive data in the coming months. Brittany Harvey: Definitely. And then you've just mentioned a few ongoing trials where we're looking for evidence to inform future updates. But thinking beyond that, into the future, what is the panel examining for future updates to this living guideline? Dr. Joshua Reuss: It's a very exciting time to be in the world of treating advanced non–small cell lung cancer, particularly patients with driver alterations, because there is so much evolving data that's changing our practice in real time, again highlighting the importance of these living guideline updates. I'd say there's many things that we're excited to see. You know, a lot of the combination regimens in EGFR-mutated non–small cell lung cancer for which there are approvals and current recommendations in our guideline, particularly osimertinib plus chemotherapy and amivantamab plus lazertinib - those are the two approved combination strategies in the front line - we are now seeing the emergence of overall survival data for those combinations. So obviously that is something that's going to be very important for the committee to review and incorporate into guideline updates. There are several new therapies coming down the road for other driver populations. We recently saw an approval for taletrectinib for ROS1 fusion–positive non–small cell lung cancer, so it's going to be important that the committee reviews the data and the publications regarding that therapy. And then there are other novel therapies that we're looking to see updated data on. There are multiple antibody-drug conjugates, which take the potent power of a chemotherapy molecule and attempt to make that targeted with an antibody targeting to a unique feature on the cancer cell. And there are several antibody-drug conjugates that are in development at various levels of promise in this space, particularly in EGFR-mutated non–small cell lung cancer, and I anticipate seeing some emerging data for that coming up in the near future as well. So really, lots to be excited in the space and lots for our committee to review to give guidance on so that these patients can really receive the top-level care wherever they are being treated in the country and throughout the world. Brittany Harvey: Yes, we'll await this new data to continue to provide optimal options for patients with stage IV non–small cell lung cancer with driver alterations. So, Dr. Reuss, I want to thank you so much for your work to rapidly and continuously update and review the evidence for this guideline and thank you for your time today. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available on the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Stephanie Reuss and Victoria Stuart noticed that companies were making big decisions about jobs, teams, and strategy without really knowing what people were doing. So they built Beamible, a platform that maps work at the task level. It helps organizations see what is working, what is slowing people down, and what actually creates value for the business. In this episode, Dart, Steph, and Vic talk about why visibility is the first step to meaningful change, how AI is transforming job design, and what it looks like to optimize rather than simply balance the needs of people and business.Steph and Vic are the co-founders and co-CEOs of Beamible. Steph is an award-winning entrepreneur and former global consultant with a background in finance, futures trading, and executive advisory. Vic is a former Google executive with expertise in strategy, technology, and workforce innovation.In this episode, Dart, Steph, and Vic discuss:- Why visibility into actual work is the first step to change- What the “bubble chart” reveals about energy and value- How AI transforms the way we think about job design- What drains employees and how to identify it- The human cost of misalignment between teams and leaders- How to design for optimization instead of balance- Shifting culture toward transparency and shared ownership- And other topics…Stephanie Reuss is the co-founder and co-CEO of Beamible. Her career spans corporate finance, consulting, and leadership roles across four continents, including positions at KPMG, the New York Mercantile Exchange, and CEB. She was named Entrepreneur of the Year by Women's Agenda and was a finalist for NSW Business Woman of the Year. Steph is known for challenging traditional workforce models, and her work has been featured in the AFR, Sydney Morning Herald, and SmartCompany.Victoria Stuart is the co-founder and co-CEO of Beamible. Before launching the company, she led industry strategy at Google and held leadership roles at Accenture and Digitas, working across technology, banking, and retail. With a background in both business and science, Vic brings a systems lens to complex workforce challenges. Her focus is on creating flexible, human-centered workplaces that are ready for the future.Resources Mentioned:Beamible: https://beamible.com/Connect with Steph and Vic:Steph's LinkedIn: https://www.linkedin.com/in/stephanie-reuss-04a8ab15Vic's LinkedIn: https://www.linkedin.com/in/victoria-stuart-76508810/Work with Dart:Dart is the CEO and co-founder of the work design firm 11fold. Build work that makes employees feel alive, connected to their work, and focused on what's most important to the business. Book a call at 11fold.com.

Im Kanton Aargau muss mindestens 1% der Kantonsfläche Auenlandschaft sein, so steht es in der Verfassung. Das Tagesgespräch ist unterwegs – im Rendezvous mit Alex Moser besuchen wir die Aue «Chly Rhy» und sprechen über Arten- und Hochwasserschutz im Wasserschloss der Schweiz. Autobahnen durchqueren den Aargau von West nach Ost und von Nord nach Süd. Oft ist daher vom «Autobahnkanton Aargau» die Rede. Doch den Aargau queren auch Aare, Reuss und Rhy. Das Wasser prägt den Kanton. Vor 22 Jahren stimmten die Aargauerinnen und Aargauer einer Vorlage deutlich zu, die verlangte, dass 1% der Kantonsfläche in Auen um- oder zurückgebaut wird. Regionalkorrespondent Alex Moser hat die Aue «Chly Rhy» in Zurzach von Anfang an beobachtet. In der Sommerserie des «Tagesgesprächs» erzählt er vor Ort, wie die Natur das Gebiet zurückerobert hat und was die Auen den Aargauerinnen und Aargauern bedeuten.

Era el siglo XIII cuando los valientes habitantes de los pueblos cercanos al río Reuss, en Suiza, enfrentaron un desafío que parecía imposible de superar. El caudaloso río había formado un valle tan profundo y traicionero que separaba a las comunidades, convirtiendo cada cruce en una aventura mortal. Los lugareños sabían que necesitaban un puente, pero la naturaleza salvaje del lugar hacía que tal empresa pareciera una locura.Como si las mismas palabras hubieran sido una invocación, una figura sombría emergió entre las rocas. Era el diablo en persona, con ojos que brillaban como brasas y una sonrisa que helaba la sangre.Descubre el desenlace de esta terrorífica historia y si tienes alguna sugerencia de leyenda que deberíamos investigar, da click aquí. Hosted on Acast. See acast.com/privacy for more information.

WWJ auto analyst John McElroy reports executives were banned from racing in the past, but Ford CEO Jim Farley and GM President Mark Reuss are pretty good at racing. Reuss set a speed record, while Farley raced Mustangs earlier this month.

En este episodio de La Verdad de las Cosas, Isa Canales platica con Betsy Reuss, psicóloga y sexóloga, sobre un caso que pone sobre la mesa los dilemas emocionales, sexuales y éticos en una relación de pareja. A partir de la carta de Gerardo, quien enfrenta un cambio radical en su vida íntima con su pareja —ahora decidida a esperar hasta el matrimonio para tener relaciones sexuales— analizamos el papel del miedo, la ansiedad y las creencias culturales sobre la sexualidad. ¿Es válido terminar una relación por esto? ¿Cómo se habla de sexo sin que suene a presión? Un episodio lleno de cuestionamientos, propuestas y reflexiones honestas. Suscríbete a nuestro canal de Youtube aquí Síguenos en redes: Somos Proceso - InstagramSomos Proceso - TikTokLa verdad de las cosas - InstagramLa verdad de las cosas - TiktokCONTACTO: somosproceso@em.agency

www.centerforgenerosity.comwww.gsbfundraising.comStrengthening charitable causes to change the world through generosity. For nearly 50 years, GSB has provided effective counsel to a wide array of non-profit entities, including congregations, camps, healthcare systems, colleges, and other agencies. We have established a formidable reputation for ethical work and consistently meeting or exceeding fundraising goals. Our approach is custom-designed to the needs of the client as well as to the culture of the client organization and constituency.

www.centerforgenerosity.comwww.gsbfundraising.comStrengthening charitable causes to change the world through generosity. For nearly 50 years, GSB has provided effective counsel to a wide array of non-profit entities, including congregations, camps, healthcare systems, colleges, and other agencies. We have established a formidable reputation for ethical work and consistently meeting or exceeding fundraising goals. Our approach is custom-designed to the needs of the client as well as to the culture of the client organization and constituency.

www.centerforgenerosity.comwww.gsbfundraising.comStrengthening charitable causes to change the world through generosity. For nearly 50 years, GSB has provided effective counsel to a wide array of non-profit entities, including congregations, camps, healthcare systems, colleges, and other agencies. We have established a formidable reputation for ethical work and consistently meeting or exceeding fundraising goals. Our approach is custom-designed to the needs of the client as well as to the culture of the client organization and constituency.

durée : 00:10:57 - Roland de Lassus : Psaumes de la Pénitence, par la Cappella Amsterdam, sous la direction de Daniel Reuss - La Cappella Amsterdam et son chef d'orchestre Daniel Reuss présentent un enregistrement complet des Psaumes de Pénitence d'Orlando di Lasso.

durée : 00:10:57 - Roland de Lassus : Psaumes de la Pénitence, par la Cappella Amsterdam, sous la direction de Daniel Reuss - La Cappella Amsterdam et son chef d'orchestre Daniel Reuss présentent un enregistrement complet des Psaumes de Pénitence d'Orlando di Lasso.

The strongest man in the world 50 years ago was Vasily Alekseyev of the Soviet Union and there he was on the cover of Sports Illustrated on April 14th, 1975. The question is… was he a nice guy? Apparently the answer was no. Because also in that issue was the 2nd part of a 4 part series from the book, “Nice Guys Finish Last,” from former player and Hall of Fame manager, Leo Durocher. The “Lip” was a heckuva ballplayer, spanning 20 years with the Yankees, Reds, Cardinals and Brooklyn Dodgers from 1925-1945. A 3-time All-Star, and 4-time World Series champion, Durocher ended his playing days as a player/manager in Brooklyn and would go on to retire as the 5th winningest skipper in MLB history. Starting in 1939 with the Dodgers and then spending 8 more years with the Nw York Giants from 1948-1955, Durocher won his only World Series as a manager when Willie Mays and the Giants swept the Cleveland Indians in 1954. The next year was his last in New York and he wouldn't manage again until the Cubs hired him in 1966. Chicago was 59-103 in his first season guiding the team but didn't have a losing season in the remainder of his 5+ seasons at the helm. He would finish his Hall of Fame managerial career in Houston with another winning season in 1973. On that '73 teams was a young lefty who started 40 games for the Astros, completing 12 of them and amassing 279 innings pitched. Jerry Reuss was just 23 years old when he played for Durocher and the two had an adventurous time together with Durocher riding his young stud as often as he could, and Reuss often questioning the tactics of the veteran manager. It was a memorable season in Houston for the southpaw who would go on to win 220 games in his 22 years in the bigs. Reuss tells us how he pranked Dave Parker when he and The Cobra met up with Muhammad Ali in an elevator while playing for the Pirates. He takes us to Candlestick Park on a warm June night in 1980 when he no-hit the Giants, and he recounts the time Ron Cey was beaned in the head by a Goose Gossage fastball in the '81 world Series. But more than anything we talk to Reuss about what was it like for a kid born in 1950 to play for a manager who had been managing in the majors for 23 years by the time their paths crossed in the Lone Star state. It was a bumpy ride to say the least. Reuss tells us that much of it was his fault and that he and Durocher didn't see eye-to-eye most of the time. He goes on to tell us that years later they met up in the office of another Dodgers manager, Tommy Lasorda, and both admitted they could have handled things differently. Reuss and The Lip patched things up and shortly thereafter, Durocher passed away.  One of the greatest managers in baseball history was a mercurial and difficult man who never finished last in his 24 years as a manager. Was it because he was a Hall of Fame manager or because only Nice Guys Finish Last? In Durocher's case… probably a little of both. Listen, download, subscribe and review the Past Our Prime podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Das soll unser Thema sein. Denken wir noch einmal an die Dichtung der Eleonore von Reuss. Die Menschen sind alle auf der Schatzsuche. Die Frage, was suchen sie eigentlich, ist vielschichtig. Die Menschen suchen Liebe, Glück, Geborgenheit, Lebenssinn, Frieden. Andere suchen Wohlstand, Geld, Lebenslust, Sexbefriedigung u. a. mehr. Für viele gilt nur eins, die anderen an die Wand zu drücken und nur für sich Vorteile zu haben. Sie meinen das sei für sie der Schatz.

V roce 1865 vyslal spisovatel Jules Verne trojici hrdinů na výpravu do vesmíru. Kniha Ze Země na Měsíc se stala asi nejznámějším dílem rané vědecké fantastiky. Málokdo ale ví, že už o devět let dříve o pouti do kosmu snil i Gustáv Reuss ze středoslovenské Revúce. Jeho rukopis je označovaný za nejstarší slovenské sci-fi. A není náhodou, že vznikl právě v Revúci, která byla v 19. století centrem příběhů a lidové představivosti.

V roce 1865 vyslal spisovatel Jules Verne trojici hrdinů na výpravu do vesmíru. Kniha Ze Země na Měsíc se stala asi nejznámějším dílem rané vědecké fantastiky. Málokdo ale ví, že už o devět let dříve o pouti do kosmu snil i Gustáv Reuss ze středoslovenské Revúce. Jeho rukopis je označovaný za nejstarší slovenské sci-fi. A není náhodou, že vznikl právě v Revúci, která byla v 19. století centrem příběhů a lidové představivosti.Všechny díly podcastu Zápisník zahraničních zpravodajů můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Would you know if you were having a heart attack? On today's podcast, Catherine Tuton and her cardiologist Dr. Christina Reuss, both chairing the Honor Ball to benefit Honor Health, share Catherine's personal story of how she survived her heart attack, and the warning signs to watch out for. Plus, in honor of Valentine's Day, Dr. Reuss offers tips for improving your heart health. BACK STORY Catherine Tuton has a passion for serving her community and making a positive impact on the lives of others. With a love for philanthropy and a heart for giving back, she has been actively involved in various charitable endeavors over the last three decades.  She embarked on her early career as an interior designer, bringing beauty and functionality into people's lives through her creative vision. However, her desire to make a difference extended far beyond the realm of interior design. She felt a calling to serve others and contribute to the betterment of society. This led her to become actively involved in a variety of charitable organizations, both in California and Arizona. She has served at Girl's Inc., A21, Phoenix Heart Ball, AHA's Women of Impact, Go Red Executive Women's Team, CASA, Working Wardrobes, UMOCA, Habitat for Humanity, St. Vincent De Paul, Arizona Costume Institute, OC Food Bank, Honor Health, as well as serves on the Honor Health Women's Board. Raised in Scottsdale, Dr. Reuss specializes in non-invasive cardiology with a special interest in pregnancy and heart conditions. She focuses exclusively on women's health and heart disease. Her goal is to empower women to take charge of their health, partnering with them along the way and offering a warm and safe environment. She creates a welcoming and safe environment where you can feel comfortable sharing your most intimate cardiac worries. She is enthusiastic to partner with OBs to care for women and help manage cardiac issues.   Website: honorhealth.com/physicians/christina-reuss https://honorhealthfoundation.org/event/honor-ball/?THB=EventDetails                     Instagram: @ YouTube:    SUBSCRIBE TO ICONIC HOUR If you enjoyed today's podcast, I'd be so appreciative if you'd take two minutes to subscribe, rate and review ICONIC HOUR. It makes a huge difference for our growth. Thanks so much!   ICONIC LIFE MAGAZINE  Stay in touch with ICONIC LIFE magazine. We invite you to join our digital VIP list and SUBSCRIBE!   JOIN OUR ICONIC COMMUNITY Website: iconiclife.com Instagram: @iconiclifemag Facebook: Iconic Life YouTube: ICONIC LIFE   FOLLOW RENEE DEE Instagram: @iconicreneedee LinkedIn: Renee Dee   Thanks for being a part of our community to Live Beautifully.